Negative Pressure Wound Therapy (for Nebraska Only)

Coverage Summary

This Nebraska-specific policy addresses outpatient use of Negative Pressure Wound Therapy (NPWT), focusing on provision of NPWT in the outpatient setting or upon discharge after an inpatient stay. It summarizes proven outpatient indications (e.g., Stage III/IV pressure injuries, neuropathic/diabetic ulcers, venous insufficiency ulcers, open surgical wounds, and high-risk open fractures such as Gustilo Grade III) when a complete wound therapy program has been tried or ruled out and documented. The policy requires documentation that the open wound has not responded to conventional treatment after 30 days before NPWT initiation and lists absolute contraindications (including active bleeding or exposed vasculature, anticoagulation therapy, eschar/necrotic tissue, exposed bone/nerves/organs, malignancy in the wound, uncontrolled soft tissue infection or untreated osteomyelitis, and an open fistula). Evidence quality across indications is heterogeneous — guideline recommendations and systematic reviews support selective outpatient use where standard care has failed, but many areas have low or variable quality evidence and some device-specific indications (single-use systems, instillation) are considered unproven.

Key thresholds and quick facts

Conventional treatment trial duration30 days

Wound depth for discontinuation<= 1 mm

Wound area reduction threshold>= 50% after minimum 4 weeks

Applicable jurisdictionNebraska

Medical-Necessity Criteria

General coverage precondition (Complete wound therapy program required prior to NPWT)

A complete wound therapy program must be tried or considered and documented prior to initiating NPWT.

Documentation of evaluation, care, and wound measurements

From required complete wound therapy elements

Application of dressings to maintain a moist wound environment

From required complete wound therapy elements

Debridement of necrotic tissue, if present

From required complete wound therapy elements

Evaluation of, and provision for, adequate nutritional status

From required complete wound therapy elements

Contraindications & Discontinuation Criteria

Contraindications (Absolute / reasons NPWT should not be used)

Absolute contraindications when any of the following are present.

Active bleeding or exposed vasculature in wound

Absolute contraindication

Anticoagulation therapy

Listed contraindication

Eschar or necrotic tissue present in wound

Listed contraindication

Exposed bone, nerves, or organs in vicinity of wound

Listed contraindication

Unproven and Not Medically Necessary Indications

Unproven and Not Medically Necessary Indications (All settings)

The following indications and devices are considered unproven and not medically necessary for NPWT in all settings. Claims for NPWT for these indications may be denied.

ANY of the following

Closed surgical incisions
Pilonidal disease
Disposable/single-use NPWT systems
NPWT systems with instillation of wound solutions

Coding

Covered/Referenced CPT (NPWT service codes)CPT

97605	Negative pressure wound therapy, utilizing durable medical equipment (DME), per session; total wound(s) surface area <= 50 sq cm
97606	Negative pressure wound therapy, utilizing DME, per session; total wound(s) surface area > 50 sq cm
97607	Negative pressure wound therapy, utilizing disposable, non-durable medical equipment, per session; total wound(s) surface area <= 50 sq cm
97608	Negative pressure wound therapy, utilizing disposable, non-durable medical equipment, per session; total wound(s) surface area > 50 sq cm

HCPCS / DME / SuppliesHCPCS

A6550	Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories
A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each
E2402	Negative pressure wound therapy electrical pump, stationary or portable
K0743-K0746	Suction pumps and dressing codes that apply to devices other than negative pressure wound therapy (coding clarification)

Informational FDA product code referencemixed

OMP	FDA product code referenced for NPWT systems (informational only)

Provider Actions and Documentation Requirements

Documentation Required

Complete wound therapy documentation required prior to NPWT

Prior to initiating outpatient NPWT, the provider must document completion of a comprehensive wound therapy program demonstrating that conventional measures were tried or considered and ruled out.

Documentation of evaluation, care, and wound measurements
Application of dressings to maintain a moist wound environment
Debridement of necrotic tissue, if present
Evaluation of, and provision for, adequate nutritional status
Provider rationale for NPWT (documentation of indication)
Documentation that the open wound has not responded to conventional treatment after 30 days

Documentation Required

Background & Evidence Summary

NPWT (vacuum-assisted wound closure) applies continuous or intermittent sub-atmospheric pressure to a sealed wound dressing connected to a suction pump, tubing, and collection chamber. The therapy is intended to remove exudate and debris, reduce bacterial contamination and local edema, approximate wound edges, increase local blood flow and stimulate granulation tissue formation — mechanisms that may accelerate wound bed preparation and support subsequent closure or grafting.

This policy emphasizes outpatient application of NPWT (including use after discharge) as an adjunct for wounds that have not responded to conventional measures. A complete wound therapy program — including documented wound evaluation and measurements, moist dressings, debridement if indicated, and nutritional assessment — must have been tried or considered and ruled out before NPWT is initiated; the policy specifically requires documentation that the open wound has not responded to conventional treatment after 30 days.

Because the evidence base is heterogeneous, the policy stresses that NPWT should be reserved for specified proven outpatient indications and that initiation should follow failure of standard care. The policy also highlights that certain applications and devices (for example, disposable/single-use NPWT systems and NPWT with instillation) are listed as unproven and not medically necessary in many settings pending higher-quality evidence, and it requires that the patient medical record fully support the medical necessity of requested services.

Citation	Key finding/limitation
Kirsner et al. 2019	Single-use NPWT (s-NPWT) showed statistically superior wound area, depth, volume reduction and higher wound closure rates versus traditional NPWT over 12 weeks (n=164); limitation: small numbers, short follow-up, and compared NPWT types rather than NPWT vs standard care.
Cochrane (pressure ulcers) - Shi et al., 2023	Very low‑certainty evidence from eight RCTs (n=327); efficacy and safety of NPWT for pressure ulcers compared to usual care are uncertain due to small sample sizes, limited data, and unclear adverse event reporting.
Wang et al. 2022 (DFUs)	Meta-analysis of RCTs showed NPWT reduced risk of non-closure, decreased wound area, increased granulation, and reduced amputation risk versus moist wound care; limitation: included relatively low-quality, small RCTs.
WHIST trial / WOLLF (complex fractures) - Costa et al., 2020/2024	Large RCTs of incisional/trauma-related NPWT showed no difference in long-term disability or complication rates versus standard dressings (WHIST: no difference in disability at 5 years; WOLLF: no difference at 12 months); limitations include follow-up attrition and heterogeneity of wounds.
WHIST randomized trial (incisional NPWT vs standard dressing) - 30/90 day outcomes	At 30 days deep SSI 5.84% (NPWT) vs 6.68% (standard); no significant difference at 90 days — authors concluded results do not support routine use of incisional NPWT for this indication; event rates lower than expected.
Meta-analyses (single-use closed‑incision NPWT) - Singh/Strugala & Martin	Some meta-analyses report reduced SSIs, seromas, dehiscence and LOS with single‑use/ciNPT, but findings limited by heterogeneity and variable study quality across included studies.
NPWTi-d systematic reviews/meta-analyses (De Pellegrin, Gabriel, Kanapathy)	NPWT with instillation (NPWTi-d) shows higher primary wound closure and fewer complications versus NPWT/standard care in pooled analyses, but evidence is low quality and heterogeneous; further high-quality RCTs needed.
Pilonidal RCT (Ensor et al. 2024)	Randomized trial (n=50) found no difference in surgical wound dehiscence, healing time, or patient outcomes between NPWT and conventional passive dressings; limitations include small, nonblinded design — evidence insufficient to support routine use.

Glossary: A Gustilo Grade III open fracture denotes an open fracture with extensive soft-tissue damage or an open segmental fracture (subtypes IIIA, IIIB, IIIC describe increasing severity and vascular injury). Stage III pressure injury involves full-thickness skin loss with visible subcutaneous fat but without exposed fascia, muscle, tendon, ligament, cartilage, or bone; Stage IV pressure injury involves full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone. NPWTi-d refers to NPWT with instillation and dwell time, where wound solutions are instilled into the wound bed and negative pressure cycles are applied; evidence for NPWTi-d shows promising higher primary closure and lower complication rates in some analyses but is limited by low-quality, heterogeneous studies. Single-use/closed-incision NPWT denotes disposable devices intended for prophylactic use over closed surgical incisions (examples include PICO and Prevena); the policy notes mixed evidence and considers many single-use applications unproven or conditionally supported depending on the indication and study quality.

Revision History

2025-12-01material revisionLatest

Added language requiring that the patient's medical record must contain documentation that fully supports the medical necessity for the requested services, including relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures; documentation must be legible, maintained in the patient's record, and made available upon request. Archived previous policy version CS157NE.L.

2025-12-01policy editLatest

Clarified that medical records documentation may be required to assess whether the member meets clinical criteria for coverage and that such documentation does not guarantee coverage of the requested service.

Evidence-based coverage considerations summarized

Summarized guideline- and evidence-linked considerations and stated strength/quality where provided.

IWGDF diabetic foot post-operative wound recommendation: Consider NPWT to reduce wound size in postoperative diabetic foot wounds in addition to best standard of care (IWGDF; Weak recommendation; Low quality evidence).

IWGDF guidance

IWGDF non-surgical DFU guidance: Suggest not using NPWT in preference to best standard of care for non-surgical diabetic foot ulcers (IWGDF; Weak recommendation; Low quality evidence).

IWGDF guidance

NPIAP/WHS pressure injury guidance: Consider NPWT for Stage III or IV pressure injuries that fail to progress with conventional therapy (NPIAP, WHS).

NPIAP/WHS recommendations; weak/level descriptors provided

SVS diabetic foot adjunctive therapy threshold: For diabetic foot ulcers failing to demonstrate >= 50% wound area reduction after minimum 4 weeks of standard therapy, consider adjunctive modalities including NPWT; for wounds not demonstrating expected progress after 4–8 weeks consider NPWT (SVS; Grade 1B/2B guidance).>= 50% after minimum 4 weeks

SVS guideline thresholds and grades

Closed-incision single-use NPWT guidance: Consider closed-incision single-use NPWT in high-risk patients to reduce SSIs and seromas; evidence heterogeneous and variable in quality (NICE, meta-analyses).

NICE and meta-analyses summary

NPWT with instillation (NPWTi-d) evidence: NPWTi-d shows promise for higher primary wound closure and lower complication rates versus NPWT or standard care in orthoplastic and other wounds, but evidence quality is low and further RCTs are needed.

NICE/De Pellegrin/Gabriel/Diehm summaries

Pilonidal disease evidence: Insufficient evidence to support routine use of NPWT for pilonidal disease; RCTs and systematic reviews show no consistent benefit.

Ensor RCT and Hayes assessments

Open fractures/orthopedic evidence mixed: For traumatic open fractures and certain orthopedic indications, RCTs and meta-analyses provide mixed findings; not uniformly supportive of incisional NPWT for all indications (e.g., WHIST trial showed no significant difference at 5 years).

WHIST and systematic review findings